The Effects of Agave Fructans in a Functional Food Consumed by Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial

被引:4
|
作者
Camacho-Diaz, Brenda Hildeliza [1 ]
Arenas-Ocampo, Martha Lucia [1 ]
Osorio-Diaz, Perla [1 ]
Jimenez-Aparicio, Antonio Ruperto [1 ]
Alvarado-Jasso, Guadalupe Monserrat [2 ]
Saavedra-Briones, Eden Valfre [3 ]
Valdovinos-Diaz, Miguel angel [4 ]
Gomez-Reyes, Elisa [5 ]
机构
[1] Inst Politecn Nacl, Ctr Desarrollo Prod Biot, Yautepec 62731, Morelos, Mexico
[2] Ctr Nacl Tecnol & Seguridad Alimentaria CNTA, Ctra NA-134 Km 53, San Adrian 31570, Navarra, Spain
[3] Univ Autonoma Estado Morelos, Fac Nutr, Cuernavaca 62290, Morelos, Mexico
[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Gastrointestinal Motilidad Lab, Dept Gastroenterol, Ciudad De Mexico 14080, Mexico
[5] Tecnol Monterrey, Escuela Med & Ciencias Salud, Campus Ciudad Mexico,Calle Puente 222, Ciudad De Mexico 14380, Mexico
关键词
IBS; constipation; prebiotic jelly; agave fructans; functional foods; prebiotics; fiber intake; intestinal movements; QUALITY-OF-LIFE; MEXICAN CONSENSUS; GUT MICROBIOTA; DIETARY FIBER; DEPRESSION; IBS; VALIDATION; ANXIETY; ALTERS;
D O I
10.3390/nu15163526
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Irritable bowel syndrome displays three different subtypes: constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M). Treatment with dietary fiber is used, with consideration given both to the chemical composition of the fiber and to the different subtypes of IBS. The IBS-D subtype is usually treated with a low-FODMAPs diet, whereas the IBS-C subtype suggests prebiotics and probiotics to promote microbiota restoration. The aim of this study was to assess the effects of employing agave fructans as the soluble fiber of a jelly (Gelyfun (R) gastro) containing 8 g per serving in the IBS-C group (n = 50), using a randomized, double-blind, time-limited trial for four weeks. We evaluated changes in the frequency and types of bowel movements through the Bristol scale, and the improvement of the condition was evaluated using quality of life (IBS-QOL) and anxiety-depression (HADS) scales. The main results were that the number of bowel movements increased by more than 80%, with at least one stool per day from fifteen days onwards, without a laxative effect for the group treated. Finally, the quality of life with the prebiotic jelly was significantly improved compared to the placebo in all specific domains, in addition to significantly reducing anxiety and depression.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Glucomannan is not effective for the treatment of functional constipation in children: A double-blind, placebo-controlled, randomized trial
    Chmielewska, Anna
    Horvath, Andrea
    Dziechciarz, Piotr
    Szajewska, Hania
    CLINICAL NUTRITION, 2011, 30 (04) : 462 - 468
  • [22] Randomized, double-blind, placebo-controlled trial of Ficus carica paste for the management of functional constipation
    Baek, Hyang-Im
    Ha, Ki-Chan
    Kim, Hye-Mi
    Choi, Eun-Kyung
    Park, Eun-Ock
    Park, Byung-Hyun
    Yang, Hye Jeong
    Kim, Min Jung
    Kang, Hee Joo
    Chae, Soo-Wan
    ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2016, 25 (03) : 487 - 496
  • [23] Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Oh, Joo Hyun
    Jang, Yeon Sil
    Kang, Danbee
    Chang, Dong Kyung
    Min, Yang Won
    NUTRIENTS, 2019, 11 (12)
  • [24] Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial
    Peng, Li Hua
    Fang, Jing Yuan
    Dai, Ning
    Shen, Xi Zhong
    Yang, You Lin
    Sun, Jing
    Yang, Yun Sheng
    JOURNAL OF DIGESTIVE DISEASES, 2022, 23 (02) : 99 - 110
  • [25] Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome
    Ballou, Sarah
    Haas, Julia W.
    Iturrino, Johanna
    Nee, Judy
    Kirsch, Irving
    Rangan, Vikram
    Cheng, Vivian
    Lembo, Anthony
    Kaptchuk, Ted J.
    Kelley, John M.
    PSYCHOSOMATIC MEDICINE, 2022, 84 (06): : 738 - 746
  • [26] Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
    Cash, Brooks D.
    Pimentel, Mark
    Rao, Satish S. C.
    Weinstock, Leonard
    Chang, Lin
    Heimanson, Zeev
    Lembo, Anthony
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (09) : 689 - 699
  • [27] Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: a randomized, double-blind, placebo-controlled trial
    Micka, Antje
    Siepelmeyer, Anne
    Holz, Anja
    Theis, Stephan
    Schoen, Christiane
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2017, 68 (01) : 82 - 89
  • [28] Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate in the Management of Constipation in Hospice Patients
    Tarumi, Yoko
    Wilson, Mitchell P.
    Szafran, Olga
    Spooner, G. Richard
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (01) : 2 - 13
  • [29] A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome
    Nyhlin, H
    Bang, C
    Elsborg, L
    Silvennoinen, J
    Holme, I
    Rüegg, P
    Jones, J
    Wagner, A
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2004, 39 (02) : 119 - 126
  • [30] Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study
    Iribarren, Cristina
    Tornblom, Hans
    Aziz, Imran
    Magnusson, Maria K.
    Sundin, Johanna
    Vigsnaes, Louise K.
    Amundsen, Ingvild Dybdrodt
    McConnell, Bruce
    Seitzberg, Dorthe
    Ohman, Lena
    Simren, Magnus
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32 (10):